Mepivacaine Production Cost Reports

The report provides a detailed analysis essential for establishing a mepivacaine production plant. It encompasses all critical aspects necessary for mepivacaine production, including the cost of mepivacaine production, mepivacaine plant cost, mepivacaine production costs, and the overall mepivacaine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a mepivacaine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Mepivacaine is an amide-type local anaesthetic with a rapid onset and intermediate duration. It is used for its minimal vasodilatory effects that reduce the need for added vasoconstrictors in many cases. It is used for local infiltration, peripheral nerve blocks, epidural, caudal, and spinal anaesthesia for short-to-medium surgical procedures that require reliable numbness without extended recovery times. It is utilised in dentistry and specialised care for medically compromised patients (to avoid blood pressure surges). It also finds its application in paediatrics (plain formulations without epinephrine) and in those with infections or sulfite allergies. It also provides lower risks of transient neurologic symptoms than lidocaine in spinal use and supports postoperative pain management via catheters. Its common side effects include numbness, tingling, anxiety, dizziness, drowsiness, blurred vision, tinnitus, tremors, nausea, vomiting, and headache.

The market for mepivacaine is influenced by demand across diverse sectors, including dental surgeries. Its utilisation in procedures like extractions and root canals, and favourable safety profile in patients with contraindications to vasoconstrictor additives contributes to its market growth. Its intermediate duration aligns with short recovery needs, obstetrics for epidural and caudal blocks during labour, and usage as veterinary anaesthesia fuels its market. Its demand in home healthcare and ambulatory segments, along with a shift toward minimally invasive techniques, boosts its demand.

The innovations in drug delivery systems, like advanced formulations including mepivacaine hydrochloride injections and nitrate variants, improve bioavailability and patient tolerance, which expands their applications. The strict cold-chain logistics to preserve injection efficacy, rigorous regulatory compliance for pharmaceutical-grade purity amid FDA and EMA oversight, and intensifying competition from generic affects industrial mepivacaine procurement.

Raw Material for Mepivacaine Production

According to the mepivacaine production plant project report, the key raw materials used in the production of mepivacaine include N-(2,6-dimethylphenyl)-2-piperidinecarboxamide, anhydrous formic acid, paraformaldehyde, hydrochloric acid, and sodium hydroxide.

Production Process of Mepivacaine

The extensive mepivacaine production cost report consists of the following major industrial production process:

1. From N-(2,6-dimethylphenyl)-2-piperidinecarboxamide: The production process of mepivacaine involves formylation of N-(2,6-dimethylphenyl)-2-piperidinecarboxamide with paraformaldehyde. The reaction takes place in anhydrous formic acid, and this is followed by the addition of paraformaldehyde. The mixture is heated, and hydrochloric acid is added after the completion of the reaction. The product is washed with toluene and basified, filtered, and concentrated to give pure mepivacaine as the final product.

Mepivacaine is an amide local anaesthetic with the molecular formula (free base) of C15H22N2O and a molecular weight of 246.35 g/mol. It is used as its hydrochloride salt that has a molecular formula of C15H23ClN2O with a molecular weight of 282.81 g/mol. It appears as a white, crystalline, odourless powder that is freely soluble in water and alcohol. It has a piperidinecarboxamide structure where N-methyl pipecolic acid bonds with 2,6-dimethylaniline. It shows moderate lipophilicity with a logP value of around 2.7. It has two hydrogen bond donors and acceptors, a topological polar surface area of 32.3 Ų. It has one chiral centre without defined stereochemistry in standard forms, and pKa values near 7.6-7.8, supporting rapid onset in acidic tissues.